Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    " September 22, 2010":" October 22, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
2 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
3 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
4 Completed
Has Results
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
5 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
6 Active, not recruiting Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Condition: HIV Infection and Chronic Alanine Aminotransferase Elevation
Intervention: Other: Fibroscan
7 Completed
Has Results
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
8 Completed
Has Results
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Interventions: Drug: Truvada;   Drug: Raltegravir
9 Unknown  Measurement of Plasma and Intracellular Concentrations of Raltegravir
Condition: HIV
Intervention: Drug: Raltegravir
10 Active, not recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
11 Terminated Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
Condition: HIV
Intervention:
12 Unknown 
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
13 Completed Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
14 Completed Multi-vitamins, HAART and HIV/AIDS in Uganda
Condition: HIV/AIDS
Intervention: Dietary Supplement: Multivitamin supplements B,C and E
15 Unknown  Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
Intervention:
16 Unknown  Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
17 Completed Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Conditions: Drug Interactions;   Human Immunodeficiency Virus
Intervention: Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
18 Unknown 
Has Results
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Raltegravir;   Drug: GSK1349572 Placebo;   Drug: Raltegravir Placebo
19 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
20 Active, not recruiting Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Condition: Reduction in Heavy Drinking in Patients With HIV
Interventions: Drug: Naltrexone;   Other: Placebo + Medication Management/Medication Coaching

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.